In summary, our study revealed that the co-administration of FGFR4 inhibitor with EZH2 inhibitor could significantly inhibit tumor growth, which may be a potential option for the future clinical treatment of HCC. This evidence concerns the gene EZH2 and hepatocellular carcinoma.